Teflaro's Key Patents and Expiration Timeline
Cefderocol (Teflaro), AbbVie's antibiotic for complicated urinary tract and intra-abdominal infections, faces patent expiry around 2031-2035 for core composition-of-matter patents, with some method-of-use protections extending later.[1] DrugPatentWatch lists U.S. Patent 9,993,535 (expires May 2035) as a primary barrier to generics, alongside formulation patents challenged in ongoing Paragraph IV litigations.[2]
AbbVie's Everchanging Strategy to Extend Market Control
AbbVie is filing secondary patents on new formulations, like extended-infusion versions, to layer protections beyond 2035. They hold 12 Orange Book-listed patents, with the latest (11,459,338) expiring in 2041, focusing on stability improvements for hospital use.[2] This "patent thicketing" mirrors AbbVie's Humira playbook, where they built 100+ patents to delay biosimilars until 2023.
Pipeline Moves: Next-Gen Cephalosporins and Combinations
AbbVie is advancing ceftobiprole (acquired via Combatech in 2022), a broad-spectrum cephalosporin in Phase 3 for Staphylococcus aureus bacteremia, positioned as a Teflaro successor with similar Gram-negative coverage but broader activity.[3] They're also pairing Teflaro with beta-lactamase inhibitors in trials, creating fixed-dose combos protected by new IP to retain share post-expiry.
Legal Defenses Against Generic Challengers
AbbVie sued Zydus and Sandoz in 2023 over ANDA filings challenging Teflaro patents, securing stays until 2026 court rulings.[2] Similar to their adalimumab wins, these suits aim for settlements granting limited generic entry, preserving revenue during transition.
Manufacturing and Supply Chain Shifts
AbbVie shifted Teflaro production to its Sligo, Ireland facility in 2021, cutting costs by 20% and boosting capacity for potential demand surges or combo launches.[4] This supports lifecycle management without U.S. reliance.
Revenue Projections and Biosimilar Risks
Teflaro generated $132 million in 2023 U.S. sales, down from peaks but stable.[1] Analysts expect 30-50% erosion post-2035 without defenses, though AbbVie's $10B+ R&D spend prioritizes antimicrobials amid stewardship pressures.[3] No biosimilars yet due to complex synthesis, but small-molecule generics loom larger.
[1]: AbbVie 2023 Annual Report, https://investors.abbvie.com/sec-filings
[2]: DrugPatentWatch.com, https://www.drugpatentwatch.com/p/tradename/TEFLARO
[3]: AbbVie Pipeline Update (Q2 2024), https://news.abbvie.com/
[4]: AbbVie Investor Presentation (2022), https://investors.abbvie.com/events-presentations